ALK and lung cancer: The current College of American Pathologist (CAP)/International Association for the Study of Lung Cancer (IASLC)/Association for Molecular Pathology (AMP) guidelines recommend screening advanced-stage lung cancer patients for targetable alterations including testing for EGFR, ALK, and ROS12.